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Staphylococcus aureus is the most frequently isolated pathogen causing bloodstream infections, skin and soft tissue infections
and pneumonia. Lymphocyte is an important immune cell. The aim of the present paper was to test the ameliorative role of
nanoconjugatedvancomycinagainstVancomycin-sensitiveStaphylococcusaureus(VSSA)andvancomycin-resistantStaphylococcus
aureus (VRSA) infection-induced oxidative stress in lymphocytes. VSSA and VRSA infections were developed in Swiss mice by
intraperitoneal injection of 5 × 106 CFU/mL bacterial solutions. Nanoconjugated vancomycin was adminstrated to VSSA- and
VRSA-infected mice at its eﬀective dose for 10 days. Vancomycin was adminstrated to VSSA- and VRSA-infected mice at a similar
dose, respectively, for 10 days. Vancomycin and nanoconjugated vancomycin were adminstrated to normal mice at their eﬀective
doses for 10 days. The result of this study reveals that in vivo VSSA and VRSA infection signiﬁcantly increases the level of lipid
peroxidation, protein oxidation, oxidized glutathione level, nitrite generation, nitrite release, and DNA damage and decreases the
level of reduced glutathione, antioxidant enzyme status, and glutathione-dependent enzymes as compared to control group, which
were increased or decreased signiﬁcantly near to normal in nanoconjugated vancomycin-treated group. These ﬁndings suggest the
potential use and beneﬁcial role of nanoconjugated vancomycin against VSSA and VRSA infection-induced oxidative stress in
lymphocytes.
1.Introduction
Staphylococcus aureus is a major human pathogen causing
signiﬁcantmorbidity andmortalityinboth community-and
hospital-acquired infections [1]. It causes a diverse array of
infections ranging from relatively minor skin and wound
infections to more serious and life-threatening diseases such
as pneumonia, endocarditis, osteomyelitis, arthritis, and
sepsis. Concerns over the emergence of multidrug-resistant
strains have renewed interest in understanding the virulence
mechanisms of this pathogen at the molecular level and
in elucidating host defense elements that either provide
protection or limit infection [2, 3]. Many staphylococcal
infections which tend to become chronic (e.g., osteomyelitis
and mastitis) are associated with multiple recurrences and
do not resolve even in the presence of what seems to be an
adequate humoral immune response [4]. S. aureus has been
shown to be ingested by nonprofessional phagocytes, such as
mouse ﬁbroblasts, mouse renal cells, and bovine mammary
epithelial cells [5, 6]. S. aureus also has the ability to invade
mouse and human osteoblast cell lines, as well as normal
mouse and human osteoblasts [7, 8].
Polymorphonuclear neutrophils (PMNs) have long been
thought to provide signiﬁcant host defense against S. aureus2 Oxidative Medicine and Cellular Longevity
infection primarily because patients who are neutropenic or
who have congenital or acquired defects in PMN function
are more susceptible to infection with this pathogen [9]. The
possibilitythatphagocytes,particularlyPMN,couldfacilitate
S.aureusinfectionhasbeenraisedbyotherinvestigators[10–
13]. In vivo studies suggested that the ability of S. aureus to
exploit the inﬂammatory response of the host by surviving
inside PMN is a virulence mechanism for this pathogen and
that modulation of the inﬂammatory response is suﬃcient
to signiﬁcantly alter morbidity and mortality induced by
S. aureus infection [14]. Till now no studies have assessed
whether survival of S. aureus inside lymphocyte occurs in
vivo and whether this can promote infection.
Chitosan (CS), the deacetylated form of chitin, is a
linear polysaccharide, composed of glucosamine and N-
acetyl glucosamine linked in a β linkage [15]. CS has been
reported to possess immune stimulating properties such as
increasing accumulation and activation of macrophages and
polymorphonuclear,suppressingtumorgrowth,augmenting
antibody responses and inducing production of cytokines
[16]. Carboxy methyl chitosan (CMC) is synthesized from
CS by carboxylation of the hydroxyl and amine groups
[17]. In our previous laboratory report, we have synthesized
carboxymethyl chitosan-2,2 -ethylenedioxy bis ethylamine-
Folate (CMC-EDBE-FA) nanoparticle based on carboxy
methyl chitosan tagged with folic acid by covalently linkage
through 2,2 -(ethylenedioxy) bis-(ethylamine); vancomycin
was loaded onto it called “nanoconjugated vancomycin” and
observe its in vitro bactericidal activity against S. aureus
[18]. In our recent laboratory report, we observed that
CMC-EDBE-FA is nontoxic and it inhibits the nitric oxide-
mediated Staphylococcus aureus pathogenesis in lymphocytes
in a dose- and duration-dependent manner [19, 20]. The
present study was aimed at testing the ameliorative role
of nanoconjugated vancomycin against VSSA- and VRSA-
induced oxidative stress in lymphocytes.
2. Results
2.1. Characterization of CMC-EDBE-FA. The peak assign-
ment of CMC was as follows: 1741cm−1 (–COOH), 1070–
1136cm−1 (–C–O), and 1624 and 1506cm−1 (–NH3
+). FA-
EDBE showed the characteristic absorption bands at 1650
and 1550cm−1 located in the zone related to the (–CONH–),
corresponding, respectively, to the (C=O) stretching band
and to the (–NH) bending vibration band. The presence
of these two bands indicates that an amide bond has been
formed between –COOH of folic acid and the –NH2 amine
end group of EDBE. The more characteristics of these
two bands have become more prominent and intense in
CMC-EDBE-FA. This provides evidence for the formation
of an extra amide bond during the attachment of folic
acid. 1H NMR spectrum of CMC-EDBE-FA showed the
peaks at about 1.9ppm attributed to the methyl hydrogen
of acetamido-2-deoxy-β-D-glucopyranosyl unit; the peaks
at about 2.9–3.2ppm attributed to methylene hydrogen
atoms of EDBE and 3.5–4ppm observed the glucopyranosyl
hydrogen atoms. It was clear the proton peaks of 8.7,
7.6, 6.9, 6.4ppm were observed in 1HN M Rs p e c t r u mo f
CMC-EDBE-FA. No such peaks were observed in the same
chemical shifts of 1H NMR spectrum for CMC. The appear-
ance of these peaks conﬁrms the successful conjugation
of FA-EDBE with CMC. The size of CMC-EDBE-FA self-
assembled nanoparticles in aqueous medium measured by
dynamic laser light-scattering (DLS) ranged from 210 ±
40nm. The morphology of CMC-EDBE-FA self-aggregated
nanoparticles was investigated by TEM. The nanoaggregate
shows a spherical geometry and having a uniform size. At
lower magniﬁcation, nanoparticles having an average size
of about 50nm were observed (Figures are not shown)
[18].
2.2. Nitrite Generation by Lymphocytes and Release in Serum.
Nitrate (NO) generation is an indicator of free radical
generation. NO generation was signiﬁcantly (P<0.05)
increased in lymphocytes by 123.56% and 149.66%, respec-
tively, due to VSSA and VRSA infection as compared to
control group, which was signiﬁcantly (P<0.05) decreased
by 48.16% and 47.19% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin decreased NO gener-
ation signiﬁcantly (P<0.05) in VSSA-infected lymphocytes
by 32.17%, but by 5.08% in VRSA-infected lymphocytes
which is not signiﬁcant. Vancomycin, at its most eﬀective
doses used in this experiment, did not induce signiﬁcantly
NO generation in normal lymphocytes; however, nanocon-
jugated vancomycin, at its most eﬀective doses used in
this experiment, signiﬁcantly decreased (P<0.05) NO
generation by 27.74% and 50.33% in normal lymphocytes
(Figure 1). NO release was signiﬁcantly (P<0.05) increased
in serum by 99.91% and 105.71%, respectively, due to VSSA
and VRSA infection as compared to control group, which
wassigniﬁcantly(P<0.05)decreasedby42.11%and42.09%
due to treatment of nanoconjugated vancomycin. Treatment
of vancomycin decreased NO release signiﬁcantly (P<0.05)
in VSSA-infected lymphocytes by 30.73%, but by 3.22% in
VRSA infected group which is not signiﬁcant. Vancomycin,
at its most eﬀective doses used in this experiment, did
not induce signiﬁcantly NO release in control groups;
however, nanoconjugated vancomycin, at its most eﬀective
doses used in this experiment, signiﬁcantly decreased (P<
0.05) NO release by 20.67% and 24.87% in normal serum
(Figure 3).
2.3. Myeloperoxidase Activity of Lymphocyte. Myeloperoxi-
dase (MPO) is an important enzyme to produce hypochlor-
ous acid (HOCl) in cellular system that leads to oxidative
damage. MPO activity was signiﬁcantly (P<0.05) increased
in lymphocytes by 92.65% and 104.28%, respectively, due
to VSSA and VRSA infection as compared to control group,
which was signiﬁcantly (P<0.05) decreased by 43.19% and
48.29% due to treatment of nanoconjugated vancomycin.
Treatment of vancomycin decreased MPO activity signiﬁ-
cantly (P<0.05) in VSSA-infected lymphocytes by 38.24%,
but by 5.37% in VRSA infected lymphocytes which is not
signiﬁcant. Vancomycin, at its most eﬀective doses used in
this experiment, did not induce signiﬁcantly MPO activity inOxidative Medicine and Cellular Longevity 3
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Figure 1: Nitrite generation (NO) in control, 100mg/kg bw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cytes. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
normallymphocytes; however,nanoconjugatedvancomycin,
at its most eﬀective doses used in this experiment, signif-
icantly decreased (P<0.05) MPO activity by 23.6% and
33.87% in normal lymphocytes (Figure 2).
2.4. Lipid Peroxidation Level in Lymphocytes. Lipid perox-
idation is an important determinant to access the cellular
damage. Lipid peroxidation in terms of malondialdehyde
(MDA) level was signiﬁcantly (P<0.05) increased in
lymphocytes by 187.23% and 228.5%, respectively, due
to VSSA and VRSA infection as compared to control
group, which was signiﬁcantly (P<0.05) decreased by
51.24% and 54.35% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin decreased MDA
levels signiﬁcantly (P<0.05) in VSSA-infected lymphocytes
by 33.49%, but by 4.05% in VRSA-infected lymphocytes
which is not signiﬁcant. Vancomycin, at its most eﬀective
doses used in this experiment, did not induce signiﬁ-
cantly lipid peroxidation in normal lymphocytes; however,
nanoconjugated vancomycin, at its most eﬀective doses
used in this experiment, signiﬁcantly decreased (P<0.05)
MDA level by 22.13% and 28.38% in normal lymphocytes
(Figure 4).
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Figure 2: Myeloperoxidase (MPO) activity in control, 100mg/kg
bw/day vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg
bw/day nanoconjugated vancomycin, 500mg/kg bw/day nanocon-
jugated vancomycin, VSSA infection control, VSSA infection +
100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocytes. Values are expressed as mean ± SEM, n = 6.
∗indicates signiﬁcant diﬀerence (P<0.05) compared to control
group. #indicates signiﬁcant diﬀerence (P<0.05) compared to
infection control group.
2.5.ProteinOxidationLevelinLymphocytes. Likelipidperox-
idation, protein oxidation is also an important determinant
to access the cellular damage. Protein oxidation in terms
of protein carbonyl (PC) level was signiﬁcantly (P<0.05)
increased in lymphocytes by 129.37% and 164.57%, respec-
t i v e l y ,d u et oV S S Aa n dV R S Ai n f e c t i o n sa sc o m p a r e dt o
control group, which was signiﬁcantly (P<0.05) decreased
by 43.71% and 47.76% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin decreased protein
carbonyl level signiﬁcantly (P<0.05) in VSSA-infected
lymphocytes by 33.68%, but by 4.99% in VRSA-infected
lymphocytes which is not signiﬁcant. Vancomycin, at its
most eﬀective doses used in this experiment, did not induce
signiﬁcantly protein oxidation in normal lymphocytes; how-
ever, nanoconjugated vancomycin, at its most eﬀective doses
used in this experiment, signiﬁcantly decreased (P<0.05)
PC level by 26.51% and 32.61% in normal lymphocytes
(Figure 5).
2.6. Glutathione Level and Redox Ratio in Lymphocytes.
Glutathione is an important antioxidant in cellular system.
So to understand glutathione level, we have measured
both reduced and oxidized forms of glutathione. Reduced4 Oxidative Medicine and Cellular Longevity
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Figure 3: Release of nitrite in control, 100mg/kg bw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated serum.
Values are expressed as mean ± SEM, n = 6. ∗indicates signiﬁcant
diﬀerence (P<0.05) compared to control group. #indicates
signiﬁcant diﬀerence (P<0.05) compared to infection control
group.
glutathione (GSH) and the redox ratio (GSH/GSSG) were
signiﬁcantly (P<0.05) diminished in lymphocytes by
51.2%, 60.71%, 73.64%, and 80.52%, respectively, due
to VSSA and VRSA infection as compared to control
group, which was signiﬁcantly (P<0.05) increased by
68.2%, 94.12%, 173.91%, and 236.76% due to treatment
of nanoconjugated vancomycin. Treatment of vancomycin
increased reduced glutathione and the redox ratio signiﬁ-
cantly (P<0.05) in VSSA-infected lymphocytes by 46.59%
and 103.26%, but by 15.03% and 26.47% in VRSA infected
lymphocytes which is not signiﬁcant (Figures 6 and 8).
Oxidized glutathione (GSSG) level was signiﬁcantly (P<
0.05) elevated in lymphocytes by 84.89% and 101.76%,
respectively,duetoVSSAandVRSAinfectionascomparedto
control group, which was signiﬁcantly (P<0.05) decreased
by 38.62% and 42.48% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin decreased oxidized
glutathione level signiﬁcantly (P<0.05) in VSSA-infected
lymphocytes by 27.87%, but by 9.07% in VRSA-infected
lymphocytes which is not signiﬁcant (Figure 7). Vancomycin
did not alter any signiﬁcant change in reduced glutathione
level, oxidized glutathione level, and redox ratio in normal
lymphocytes at its eﬀective doses used in this experiment.
Nanoconjugated vancomycin, at its most eﬀective doses
Control
100mg/kg bw Van
500mg/kg bw Van
100mg/kg bw NV
500mg/kg bw NV
VSSA
VSSA + 100mg/kg bw Van
VSSA + 100mg/kg bw NV
VRSA
VRSA + 500mg/kg bw Van
VRSA + 500mg/kg bw NV
∗ ∗
∗
∗
#
# #
0
20
40
60
80
100
120
140
160
180
(
n
m
o
l
/
m
g
p
r
o
t
e
i
n
)
Figure 4:Lipidperoxide (MDA)level incontrol,100mg/kgbw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cyte. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
used in this experiment, signiﬁcantly increased (P<0.05)
reduced glutathione level and redox ratio by 30.4%, 51.93%,
68.48%, and 118.05% and signiﬁcantly decreased (P<0.05)
oxidized glutathione level by 22.71% and 30.4% in normal
lymphocytes (Figures 6–8).
2.7. Antioxidant Enzyme Status in Lymphocytes. The super
oxide dismutase (SOD), catalase (CAT), glutathione perox-
idase (GPx), glutathione reductase (GR), and glutathione-s-
transferase (GST) were measured to understand the antiox-
idant enzymes status of diﬀerent experimental group of
lymphocytes. SOD, CAT, GPx, GR, and GST activity were
signiﬁcantly (P<0.05) diminished in lymphocytes by
44.65%, 54.41%, 64.24%, 50.83%, 50.01%, and 51.12%,
65.85%, 66.63%, 56.47%, 53.55%, respectively, due to
VSSA and VRSA infection as compared to control group,
which was signiﬁcantly (P<0.05) increased by 67.37%,
83.28%, 136.99%, 75.93%, 71.27%, and 79.29%, 129.08%,
184.31%, 94.13%, 86.35% due to treatment of nanoconju-
gated vancomycin. Treatment of vancomycin increased all
these antioxidant enzymes activity signiﬁcantly (P<0.05)
in VSSA-infected lymphocytes by 48.3%, 44.37%, 71.96%,
44.74%, and 36.99%, but by 8.52%, 13.84%, 6.65%, 7.66%,
and 9.11% in VRSA-infected lymphocytes which is notOxidative Medicine and Cellular Longevity 5
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Figure 5:ProteinCarbonyl(PC)levelincontrol,100mg/kgbw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cyte. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
signiﬁcant. Vancomycin, at its most eﬀective doses used
in this experiment, did not alter any signiﬁcant change in
these antioxidant enzyme activity, however, nanoconjugated
vancomycin, at its most eﬀective doses used in this exper-
iment, signiﬁcantly increased (P<0.05) these antioxidant
enzymes activity by 22.5%, 35.4%, 27.08%, 32.92%, 31.73%
and 29.22%, 48.23%, 38.91%, 52.11%, 48.14% in normal
lymphocytes (Figures 9–13).
2.8. Detection of Lymphocyte Apoptosis by DNA Fragmenta-
tion. DNA fragmentation is an indicator of apoptotic cell
death; hence the quantitative and qualitative DNA fragmen-
tation in lymphocyte was evaluated in this study. Quanti-
tative DNA fragmentation in all groups of lymphocyte was
evaluated by diphenylamine (DPA) assay spectrophotomet-
rically. VSSA and VRSA infection produced 461.58% and
521.52% fragmented DNA, whereas control group showed
negligible fragmented DNA in lymphocyte that was associ-
ated signiﬁcantly (P<0.05). Treatment of nanoconjugated
vancomycin signiﬁcantly (P<0.05) decreased DNA frag-
mentation by 68.84% and 69.55%, respectively. Treatment
of vancomycin decreased DNA fragmentation signiﬁcantly
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Figure 6: Reduced glutathione (GSH) level in control, 100mg/kg
bw/day vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg
bw/day nanoconjugated vancomycin, 500mg/kg bw/day nanocon-
jugated vancomycin, VSSA infection control, VSSA infection +
100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
(P<0.05) in VSSA-infected lymphocytes by 47.3%,
but by 8.05% in VRSA-infected lymphocytes which is
not signiﬁcant. Vancomycin, at its most eﬀective doses
used in this experiment, did not induce signiﬁcantly DNA
fragmentation in normal lymphocytes; however, nanocon-
jugated vancomycin, at its most eﬀective doses used in
this experiment, signiﬁcantly decreased (P<0.05) DNA
fragmentation by 27.58% and 32.85% in normal lympho-
cytes (Figure 14). To conﬁrm the data obtained from the
spectrophotometric method, we have analyzed the DNA
fragmentation by DNA laddering in 1.2% agarose gel
electrophoresis. Agarose gel electrophoresis of DNA, isolated
from lymphocytes of VSSA- and VRSA-infected lympho-
cytes, showed the presence of typical DNA ladder (hall mark
of apoptosis), while the DNA of normal lymphocytes did not
showanyladder.Wehavefoundthenegligible smearofDNA
in nanoconjugated vancomycin-treated group (Figure 15).
3. Discussion
S. aureus has long been considered as an extracellular
pathogen, which may occasionally survive and even multiply6 Oxidative Medicine and Cellular Longevity
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Figure 7: Oxidized glutathione (GSSG) level in control, 100mg/kg
bw/day vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg
bw/day nanoconjugated vancomycin, 500mg/kg bw/day nanocon-
jugated vancomycin, VSSA infection control, VSSA infection +
100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
within phagocytes resulting in prolonged and recurrent
infections [21]. It is one of the most successful human
pathogen with the ability to colonize and infect both
hospitalized patients with or without compromised host
defenses and healthy immunologically competent people
in the community [22]. However, S. aureus may occa-
sionally become intracellular, at least within monocytes,
macrophages, and polymorphonuclear neutrophils (PMNs)
when host defense mechanisms are activated [23]. Our
previous lab report showed that lymphocyte is susceptible
to S. aureus infection through generation of nitric oxide,
and the infection was successfully eliminated by treatment
of nanoconjugated vancomycin in a dose- and duration-
dependent manner [20]. In this context, our present study
proves to be more relevant and will help further study
in investigating the ameliorative role of nanoconjugated
vancomycinagainstVSSAandVRSAinducedoxidativestress
in lymphocytes.
CMC-EDBE-FA nanoparticles were prepared by the
carboxylic group (–COOH) of folic acid and –COOH
group of functionalized carboxymethyl chitosan con-
nected through the end-amino groups hydrophilic spacer,
2,2 -(ethylenedioxy)-bis-ethylamine. It is well known that
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Figure 8: Redox ratio (GSH/GSSG) in control, 100mg/kg bw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cyte. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
carboxymethyl chitosan is easily soluble in water but folic
acid has less solubility in water. When carboxymethyl
chitosan is connected by folic acid through a spacer, car-
boxymethyl chitosan may act as a hydrophilic part and folic
acid as a hydrophobic part. It is evident from our study
that, in vivo VSSA and VRSA infection in mice lympho-
cytes is associated with enhanced nitrate generation, nitrate
release, MPO activity, MDA level, PC level, GSSG level, and
decreased GSH level, and as well as decreased enzymatic
antioxidant (SOD, CAT, GPx, GR, and GST) activity, which
areamelioratedbytreatmentofnanoconjugatedvancomycin
(Figures 1–13). Moreover, DNA damage assessed by DPA
assay and agarose gel electrophoresis due to VSSA and
VRSA infection was also observed in lymphocytes, which
are protected by treatment of nanoconjugated vancomycin
(Figures 14 and 15).
In this study, a signiﬁcant elevation of nitrate generation,
MPO activity in lymphocyte, and nitrate release in serum
was observed in VSSA- and VRSA-infected mice, whereas
nitrate generation, MPO activity in normal lymphocytes,
and nitrate release in normal serum was decreased in
nanoconjugated vancomycin-treated group. Treatment of
nanoconjugated vancomycin to VSSA- and-VRSA infectedOxidative Medicine and Cellular Longevity 7
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Figure 9: Superoxide dismutase (SOD) activity in control,
100mg/kg bw/day vancomycin, 500mg/kg bw/day vancomycin,
100mg/kg bw/day nanoconjugated vancomycin, 500mg/kg bw/day
nanoconjugated vancomycin, VSSA infection control, VSSA infec-
tion + 100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
mice decreased NO generation, MPO activity signiﬁcantly
in lymphocytes, and nitrate release in serum (Figures 1–
3). Nitric oxide (NO) is a free radical synthesized by nitric
oxide synthase (NOS). NOS is composed of two identical
monomers with molecular weights ranging from 130 to
160kDa [24]. Our previous study had shown that nitric
oxide synthesis in lymphocytes and release in serum is high
during VSSA and VRSA infection, which can be related to
an alteration in oxidant-antioxidant potential [20]. Thus,
higher level of nitrite release by VSSA and VRSA infection
may be due to high production of free radicals, mainly NO.
Nanoconjugated vancomycin plays the role of antioxidant to
prevent the nitrate generation may be through the inhibition
of inducible nitric oxide synthase (iNOS) expression [25].
Hypochlorous acid (HOCl) is generated in the presence of
myeloperoxidase and initiates the deactivation of antipro-
teases and the activation of latent proteases and leads to
the cellular damage [26]. In this study, nanoconjugated
vancomycin inhibited the myeloperoxidase activity which
was increased due to VSSA and VRSA infection, suggesting
a protective role of nanoconjugated vancomycin (Figure 2).
These results suggest that either the cellular antioxidants
level reached in a higher concentration in lymphocyte exert
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Figure 10: Catalase (CAT) activity in control, 100mg/kg bw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cyte. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
antioxidant eﬀects or scavenged the free radical produced by
the myeloperoxidase [27]. Thus, in addition to the cellular
antioxidant system, nanoconjugated vancomycin may indi-
rectly protect lymphocyte from VSSA- and VRSA-infection-
induced cellular changes. Thus, free radical depletion by the
antioxidant agents seems to be beneﬁcial for preventing the
damage of lipid and protein.
In this study, signiﬁcant elevation of malondialdehyde
(MDA) and protein carbonyl level was observed in lym-
phocyte of VSSA- and VRSA-infected mice; whereas MDA
a n dP Cl e v e l si nn o r m a ll y m p h o c y t e sw e r ed e c r e a s e di n
nanoconjugated vancomycin-treated group. Treatment of
nanoconjugated vancomycin to VSSA- and VRSA-infected
mice decreased lipid peroxidation and protein oxidation
signiﬁcantly in lymphocytes (Figures 4 and 5). It may be due
to the generation of free radicals (mainly NO) which may
react with protein in addition to lipids. Lipid peroxidation
is known to disturb the integrity of cellular membranes;
leading to the leakage of cytoplasmic enzymes [28]. Protein
carbonyls formation has been indicated to be an earlier
marker of protein oxidation. Oxidation of protein may be
due to either excessive oxidation of proteins or decreased
capacity to clean up oxidative-damaged proteins. Oxidative8 Oxidative Medicine and Cellular Longevity
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Figure 11: Glutathione peroxidase (GPx) activity in control,
100mg/kg bw/day vancomycin, 500mg/kg bw/day vancomycin,
100mg/kg bw/day nanoconjugated vancomycin, 500mg/kg bw/day
nanoconjugated vancomycin, VSSA infection control, VSSA infec-
tion + 100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
modiﬁcation of proteins may lead to the structural alteration
andfunctionalinactivationofmanyenzymeproteins[29],as
evidenced by the decreased activity of diﬀerent antioxidant
enzymes like SOD, CAT, GPx, GR, and GST.
Reactive oxygen species (ROS) are generated during
oxidative metabolism and can inﬂict damage on all classes of
cellular macromolecules and eventually leading to cell death.
An elevation in free radical formation can be accompanied
by an immediate compensatory increase in the activities
of the free radical scavenging enzymes [30]. Imbalance
between the generation of reactive oxygen species (ROS) and
the antioxidant system causes oxidative stress. Glutathione,
an important cellular reductant, is involved in protection
against free radicals, peroxides, and toxic compounds in
cellular systems [31]. In the present study, the reduced glu-
tathione level and redox ratio were signiﬁcantly decreased in
lymphocyteofVSSA-andVRSA-infectedmice,whereasGSH
level and redox ratio in normal lymphocytes were increased
in nanoconjugated vancomycin-treated group. Treatment of
nanoconjugated vancomycin to VSSA and VRSA infected
mice increased the GSH level and redox ratio in lymphocytes
(Figures 6–8). In this study, it was observed that oxidized
glutathione level was increased in VSSA- and VRSA-infected
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Figure 12: Glutathione reductase (GR) activity in control,
100mg/kg bw/day vancomycin, 500mg/kg bw/day vancomycin,
100mg/kg bw/day nanoconjugated vancomycin, 500mg/kg bw/day
nanoconjugated vancomycin, VSSA infection control, VSSA infec-
tion + 100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
lymphocytes, which was ameliorated due to nanoconjugated
vancomycin treatment. GSSG level in normal lymphocytes
was decreased in nanoconjugated vancomycin-treated group
(Figure 7). The decreased GSH levels represent its increased
utilization due to VSSA and VRSA infection. On the other
hand, decreasing GSH level may be due to increasing level of
lipid oxidation products which may be associated with less
availabilityofNADPHrequiredfortheactivityofglutathione
reductase (GR) to transform GSSG to GSH [32]d u et o
the increasing production of ROS in form of NO. In our
present study, the increasing levels of GSSG and decreasing
GRactivity(Figure 12)duetoVSSAandVRSAinfectionmay
support the explanation.
Antioxidant enzymes are considered to be a primary
defensethatpreventsbiologicalmacromoleculesfromoxida-
tive damage. SOD rapidly dismutates superoxide anion
(O2
.−)t ol e s sd a n g e r o u sH 2O2, which is further degraded
by CAT and GPx to water and oxygen [33]. The results
of the present study showed a signiﬁcant fall in SOD
and CAT activities in lymphocyte of VSSA- and VRSA-
infected group; where as SOD and CAT activities in normal
lymphocyteswereincreasedinnanoconjugatedvancomycin-
treated group. Treatment of nanoconjugated vancomycin toOxidative Medicine and Cellular Longevity 9
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Figure 13: Glutathione-s-transferase (GST) activity in control,
100mg/kg bw/day vancomycin, 500mg/kg bw/day vancomycin,
100mg/kg bw/day nanoconjugated vancomycin, 500mg/kg bw/day
nanoconjugated vancomycin, VSSA infection control, VSSA infec-
tion + 100mg/kg bw/day vancomycin, VSSA infection + 100mg/kg
bw/day nanoconjugated vancomycin, VRSA infection control,
VRSAinfection+500mg/kgbw/dayvancomycin,VRSAinfection+
500mg/kg bw/day nanoconjugated vancomycin for 10-day treated
lymphocyte. Values are expressed as mean ±SEM,n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
VSSA- and VRSA-infected mice signiﬁcantly increased the
SOD and CAT activity in lymphocytes (Figures 9 and 10).
SOD, dismutate O2
.− and the same in turn, is a potent
inhibitorofCAT[34].ThedepletioninSODactivitywasmay
be due to dispose oﬀ the free radicals, produced due to VSSA
and VRSA infection. Beside this, during infection, H2O2
producedbydismutationofsuperoxideanionmayhavebeen
eﬃciently converted to O2 by CAT and the enzyme activities
showed a marked reduction. The depletion of antioxidant
enzyme activity was may be due to inactivation of the
enzyme proteins by VSSA and VRSA infection-induced
NO generation, depletion of the enzyme substrates, and/or
downregulation of transcription and translation processes.
GPx works nonspeciﬁcally to scavenge and decom-
pose excess hydroperoxides including H2O2, which may
be prevalent under oxidative stress [35–37]. Glutathione-S-
transferase(GST)mainlydetoxiﬁeselectrophiliccompounds
[38] and has a well-established role in protecting cells
from mutagens and carcinogens as a free radical scavenger
along with glutathione. In the present study, the signiﬁcant
decreasing of GSH level and GSH-dependent enzymes, that
is,GPx,GR,andGST(Figures11–13)inlymphocyteofVSSA
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Figure 14: Quantitative estimation of DNA fragmentation assay
by diphenylamine (DPA) assay in control, 100mg/kg bw/day
vancomycin, 500mg/kg bw/day vancomycin, 100mg/kg bw/day
nanoconjugated vancomycin, 500mg/kg bw/day nanoconjugated
vancomycin, VSSA infection control, VSSA infection + 100mg/kg
bw/day vancomycin, VSSA infection + 100mg/kg bw/day nanocon-
jugated vancomycin, VRSA infection control, VRSA infection +
500mg/kg bw/day vancomycin, VRSA infection + 500mg/kg
bw/day nanoconjugated vancomycin for 10-day treated lympho-
cyte. Values are expressed as mean ± SEM, n = 6. ∗indicates
signiﬁcant diﬀerence (P<0.05) compared to control group.
#indicates signiﬁcant diﬀerence (P<0.05) compared to infection
control group.
and VRSA infection may be due to increased utilization
to scavenge the free radical generation. The results of the
present study showed a signiﬁcant fall of GPx, GR, and GST
activities in lymphocyte of VSSA- and VRSA-infected group,
whereas GPx, GR, and GST activities in normal lympho-
cytes were increased in nanoconjugated vancomycin treated
group. Treatment of nanoconjugated vancomycin to VSSA-
andVRSA-infectedmicesigniﬁcantlyincreasedtheGPx,GR,
and GST activity in lymphocytes (Figures 11–13). In the
present study, it was observed that MDA level (Figure 4)a n d
DNA fragmentation (Figures 14 and 15) were signiﬁcantly
elevated in lymphocytes due to VSSA and VRSA infection.
This elevated MDA level decreases GSH level (Figure 6)
and SOD activity (Figure 9), which may be associated with
DNA fragmentation in lymphocytes. In this study, it was
observed that DNA fragmentation increased in VSSA- and
VRSA-infected lymphocytes, which was brought back near
to control due to nanoconjugated vancomycin treatment.
DNA fragmentation in normal lymphocytes was decreased
in nanoconjugated vancomycin-treated group (Figure 14).
In conclusion, in the study described here, lymphocytes
are susceptible to S. aureus infection through the increased10 Oxidative Medicine and Cellular Longevity
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Figure 15:DN Afragme ntatio nstud yb yagar oseg elelectr o p ho r esis
in control, 100mg/kg bw/day vancomycin, 500mg/kg bw/day
vancomycin, 100mg/kg bw/day nanoconjugated vancomycin,
500mg/kg bw/day nanoconjugated vancomycin, VSSA infection
control, VSSA infection + 100mg/kg bw/day vancomycin, VSSA
infection + 100mg/kg bw/day nanoconjugated vancomycin, VRSA
infectioncontrol,VRSAinfection+500mg/kgbw/dayvancomycin,
VRSA infection + 500mg/kg bw/day nanoconjugated vancomycin
for 10-day treated lymphocyte. Values are expressed as mean ±
SEM, n = 6. ∗indicates signiﬁcant diﬀerence (P<0.05) compared
to control group. #indicates signiﬁcant diﬀerence (P<0.05)
compared to infection control group.
production of nitric oxide which leads to decreased antioxi-
dant status in cell, and nanoconjugated vancomycin protects
the lymphocytes from such infection by decreasing free
radical generation, lipid and protein damage, and also by
increasingtheantioxidantstatus.Hence,thenanoconjugated
vancomycin can be used as a potent free radical scavenger
antioxidative product and can be used as a potential
therapeutic agent against staphylococcal infection.
4.MaterialsandMethods
4.1. Chemicals and Reagents. Sodium dodecyl sulfates
(SDS), 2,4-dinitrophenyl hydrazine (DNPH), 5 ,5 -dithio
(bis)-2-nitrobenzoic acid (DTNB), standard reduced glu-
tathione (GSH), glutathione reductase (GR), NADPH
Na4, NADPH, oxidized glutathione (GSSG), agarose, folic
acid (FA),Chitosan (medium molecular weight), dicy-
clohexyl carbodiimide (DCC), Triﬂuoroacetic acid, 2,2 -
(ethylenedioxy)-bis-(ethylamine) (EDBE), di-tert-butyldi-
carbonate (BoC2O), N-hydroxysuccinimide (NHS) and
1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide Hydro-
chloride (EDC), RNase A, and Proteinase K were purchased
from Sigma Chemical Co., USA. Sodium chloride (NaCl),
sodium dodecyl sulfate, ethylene diamine tetra acetate
(EDTA), tryptic soy broth, luria broth, mannitol salt agar,
agar powder, sucrose, magnesium chloride (MgCl2), sodium
azide (NaN3), phenol/chloroform/iso-amyl alcohol, ethid-
i u mb r o m i d e ,a n db r o m o p h e n o lb l u ew e r ep u r c h a s e df r o m
Himedia, India. Tris-HCl, Tris buﬀer, potassium dihydrogen
phosphate (KH2PO4), di potassium hydrogen phosphate
(K2HPO4), sodium hydroxide (NaOH), sodium acetate,
ammonium acetate, alcohol, sulfanilamide, phosphoric acid,
N-C-1 naphthyl ethylene diamine dihydrochloride, dipheny-
lamine (DPA), glycerol, boric acid, O-phenylenediamine,
and other chemicals were procured from Merck Ltd., SRL
Pvt. Ltd., Mumbai, India. All other chemicals were from
Merck Ltd., SRL Pvt., Ltd., Mumbai and were of the highest
grade available.
4.2. Animals. Experiments were performed using Swiss male
mice 6–8 weeks old, weighing 20–25g. The animals were
fed standard pellet diet and water was given ad libitum and
housed in polypropylene cage (Tarson) in the departmental
animalhousewith12hlight:darkcycle,andthetemperature
of 25 ± 2◦C. The animals were allowed to acclimatize for one
week. The animals used did not show any sign of malignancy
or other pathological processes. Animals were maintained in
accordance with the guidelines of the National Institute of
Nutrition, Indian Council of Medical Research, Hyderabad,
India and approved by the ethical committee of Vidyasagar
University.
4.3. Bacterial Strain. We used coagulase-positive vancomy-
cin-sensitive and -resistant Staphylococcus aureus strains that
were isolated from human postoperative pus sample [39].
These bacterial strains were grown at 37◦C for overnight
in tryptic soy broth. The bacterial culture was centrifuged
at 15,000rpm for 15 minutes. The pellet was resuspended
and washed with sterile phosphate buﬀer saline (PBS).
Using a UV-spectrophotometer (Schimadzu, USA) at an
absorbance of 620nm, we adjusted the viable bacterial
count to approximately 1.0 × 109 colony-forming units
(CFU)/mL, which corresponded to an optical density of 1.6.
The bacterial suspension was adjusted by serial dilution in
phosphate buﬀer saline (PBS) to give a ﬁnal concentration of
approximately 5×106 in 100μL of bacterial suspension [14].
4.4. Preparation of CMC-EDBE-FA Nanoparticle and Loading
of Vancomycin. CMC-EDBE-FA nanoparticle was prepared,
and vancomycin was loaded onto it according to our
previous laboratory report [18].
4.5. Development of VSSA and VRSA Infection in Swiss Mice.
VSSA and VRSA infection was developed in male Swiss
mice by intraperitoneal (i.p.) injection of 100μLo fb a c t e r i a l
suspension containing 5 × 106 CFU/mL according to our
previous laboratory report [20].
4.6. Experimental Design. VSSA- and VRSA-infected mice
were treated with nanoconjugated vancomycin for successive
10daysatadoseof100mg/kgbw/dayand500mg/kgbw/day,
respectively. The dose and duration of nanoconjugated
vancomycin was selected from our previous laboratoryOxidative Medicine and Cellular Longevity 11
report [20]. The following groups were considered for the
experiment.
Group I: Control.
Group II: 100mg/kg bw/day vancomycin.
Group III: 500mg/kg bw/day vancomycin.
Group IV: 100mg/kg bw/day nanoconjugated van-
comycin.
Group V: 500mg/kg bw/day nanoconjugated vanco-
mycin.
Group VI: VSSA infection.
Group VII: VSSA infection + 100mg/kg bw/day van-
comycin.
Group VIII: VSSA infection + 100mg/kg bw/day na-
noconjugated vancomycin.
Group IX: VRSA infection.
Group X: VRSA infection + 500mg/kg bw/day van-
comycin.
Group XI: VRSA infection + 500mg/kg bw/day na-
noconjugated vancomycin.
After the termination of experiment, animals were sacri-
ﬁced by an intraperitoneal injection of sodium pentobarbital
(60–70mg/kg body weight) [40], and blood (n = 6/group)
was used for preparation of serum and separation of lym-
phocyte for biochemical estimation of oxidative parameters.
4.7. Separation of Serum and Lymphocyte. Serum was ob-
tained by centrifugation of blood samples taken without
anticoagulant at 1500g for 15min and was kept at −86◦Cf o r
thefurtherestimation.Heparinizedbloodsampleswereused
fortheseparationofLymphocyte.Lymphocyteswereisolated
from blood using standard isolation techniques [41]. Blood
samples were diluted with equal amount of PBS (pH 7.0)
buﬀer and then layered very carefully on the density gradient
(Histopaque 1077, Sigma Chemical Co.) in 1:2 ratio. It
was centrifuged at 500g for 20min and the white milky
layer of mononuclear cells that is, lymphocytes was carefully
removed. The layer was washed twice with the same buﬀer
andcentrifugedat3000gfor10mintogettherequiredpellet
oflymphocytes[42].Thepelletsoflymphocyteswerelysedin
ahypotoniclysisbuﬀerfor45minat37◦Candk eptat−86◦C
until biochemical estimations [42].
4.8. Biochemical Estimation
4.8.1. Nitrite (NO) Production by Lymphocyte. After treat-
ment schedule, 100μL of Griess reagent (containing 1 part
of 1% sulfanilamide in 5% phosphoric acid, and 1 part
of 0.1% of N-C-1 napthyl ethylene diamine dihydrochlo-
ride) was added to 100μL of sample, incubated at room
temperature for 10 minutes, readings were taken in a UV
spectrophotometer at 550nm and compared to a sodium
nitrite standard curve (values ranging between 0.5 and
25μM ) .T h el ev e l so fN Ow e r ee x p r e s s e da sμmol/mg protein
[43].
4.8.2. Determination of Myeloperoxidase Activity in Lympho-
cyte. 200μLo fc e l ll y s a t ew a sr e a c t e dw i t h2 0 0μLs u b s t r a t e
(containing H2O2 and OPD) in dark for 30min. The blank
was prepared with citrate phosphate buﬀer (pH 5.2) and
substrate, in absence of cell-free supernatant. The reaction
was stopped with addition of 100μL 2(N) sulfuric acid and
reading was taken at 492nm in a spectrophotometer [44].
The MPO activity was expressed in terms of μM/mg protein.
4.8.3. Determination of Lipid Peroxidation (MDA). Lipid
peroxidation was estimated by the method of Kar Mahapa-
tra et al., 2009 [44]. Brieﬂy, the reaction mixture contained
Tris-HCl buﬀer (50mM, pH 7.4), tetra-butyl hydroperoxide
(BHP)(500μMinethanol),and1mMFeSO4.Afterincubat-
ing the samples at 37◦C for 90min, the reaction was stopped
by adding 0.2mL of 8% sodium dodecyl sulfate (SDS)
followed by 1.5mL of 20% acetic acid (pH 3.5). The amount
of malondialdehyde (MDA) formed during incubation was
estimated by adding 1.5mL of 0.8% TBA and furtherheating
the mixture at 95◦C for 45min. After cooling, samples
were centrifuged, and the TBA reactive substances (TBARS)
were measured in supernatants at 532nm by using 1.53 ×
105 M−1 cm−1 as extinction coeﬃcient. The levels of lipid
peroxidation were expressed in terms of μmol/mg protein.
4.8.4. Determination of Protein Carbonyls (PC) Contents in
Lymphocyte. Protein oxidation was monitored by measur-
ing protein carbonyl contents by derivatization with 2,4-
dinitrophenyl hydrazine (DNPH) [44]. In general, cell lysate
proteins in 50mM potassium phosphate buﬀer, pH 7.4, were
derivatized with DNPH (21% in 2N HCl). Blank samples
weremixedwith2NHClincubatedat1hinthedark;protein
was precipitated with 20% trichloro acetic acid (TCA).
Underivatized proteins were washed with an ethanol:ethyl
acetate mixture (1:1). Final pellets of protein were dissolved
in 6N guanidine hydrochloride, and absorbance was mea-
sured at 370nm. Protein carbonyls content was expressed in
terms of μmol/mg protein.
4.8.5. Determination of Reduced Glutathione (GSH). Re-
duced glutathione estimation in cell lysate was performed
by the method of Kar Mahapatra et al., 2009 [44]. The
required amount of sample was mixed with 25% of TCA and
centrifuged at 2,000×g for 15min to settle the precipitated
proteins. The supernatant was aspirated and diluted to
1mL with 0.2M sodium phosphate buﬀer (pH 8.0). Later,
2mL of 0.6mM DTNB was added. After 10 minutes, the
optical density of the yellow-colored complex formed by the
reactionofGSHandDTNB(Ellman’sreagent)wasmeasured
at 405nm. A standard curve was obtained with standard
reduced glutathione. The levels of GSH were expressed as μg
of GSH/mg protein.
4.8.6. Determination of Oxidized Glutathione (GSSG). The
oxidized glutathione level was measured after derivatization
of GSH with 2-vinylpyidine according to the method of Kar
Mahapatra et al., 2009 [44]. In brief, with 0.5mL sample,
2μL of 2-vinylpyidine was added and incubated for 1hr12 Oxidative Medicine and Cellular Longevity
at 37◦C. Then the mixture was deproteinized with 4%
sulfosalicylic acid and centrifuged at 1,000×gf o r1 0 m i n
to settle the precipitated proteins. The supernatant was
aspirated, and GSSG level was estimated with the reaction of
DTNB at 412nm in spectrophotometer and calculated with
standard GSSG curve. The levels of GSSG were expressed as
μg of GSSG/mg protein.
4.8.7. Activity of Super Oxide Dismutase (SOD). Superoxide
dismutase (SOD) activity was determined from its ability
to inhibit the auto-oxidation of pyrogalol according to
Gautam et al., 2010 [45]. The reaction mixture consid-
ered of 50mM Tris (hydroxymethyl) amino methane (pH
8.2), 1mM diethylenetriamine penta acetic acid, and 20–
50μL of sample. The reaction was initiated by addition of
0.2mM pyrogalol, and the absorbance measured kinetically
at 420nm at 25◦C for 3min. SOD activity was expressed as
unit/mg protein.
4.8.8. Activity of Catalase (CAT). Catalase activity was mea-
sured in the cell lysate by the method of Gautam et al., 2010
[45]. The ﬁnal reaction volume of 3mL contained 0.05M
Tris-buﬀer, 5mM EDTA (pH 7.0), and 10mM H2O2 (in
0.1M potassium phosphate buﬀe r ,p H7 . 0 ) .A b o u t5 0μLo f
samplewasaddedtotheabovemixture.Therateofchangeof
absorbanceperminat240nmwasrecorded.Catalaseactivity
was calculated by using the molar extinction coeﬃcient of
43.6M−1 cm−1 for H2O2. The level of CAT was expressed in
terms of μmol H2O2 consumed/min/mg protein.
4.8.9. Activity of Glutathione Peroxidase (GPx). Glutathione
peroxidase (GPx) activity was measured by the method of
Gautam et al., 2010 [45]. The reaction mixture contained
50mM potassium phosphate buﬀer (pH 7.0), 1mM EDTA,
1mM sodium azide, 0.2mM NADPH, 1U glutathione
reductase, and 1mM reduced glutathione. The sample, after
itsaddition,wasallowedtoequilibratefor5minat25◦C.The
reaction was initiated by adding 0.1mL of 2.5mM H2O2.
Absorbance at 340nm was recorded for 5min. Values were
expressed as n mol of NADPH oxidized to NADP by using
the extinction coeﬃcient of 6.2 × 103 M−1 cm−1 at 340nm.
The activity of GPx was expressed in terms of n mol NADPH
consumed/min/mg protein.
4.8.10. Activity of Glutathione Reductase (GR). Glutathione
reductase (GR) activity was measured by the method of
Gautam et al., 2010 [45]. The tubes for enzyme assay were
incubated at 37◦C and contained 2.0mL of 9mM GSSG,
0.02mL of 12mM NADPH Na4,2 . 6 8 m Lo f1 / 1 5 Mp h o s -
phate buﬀer (pH 6.6), and 0.1mL of sample. The activity of
this enzyme was determined by monitoring the decrease in
absorbance at 340nm. The activity of GR was expressed in
terms of n mol NADPH consumed/min/mg protein.
4.8.11. Activity of Glutathione-s-Transferase (GST). Gluta-
thione-s-transferase (GST) activity was measured by the
method of Gautam et al., 2010 [45]. The tubes of enzyme
assay were incubated at 25◦C and contained 2.85mL of
0.1M potassium phosphate (pH 6.5) containing 1mM of
GSH, 0.05mL of 60mM 1-chloro-2,4-dinitrobengene, and
0.1mLofsample.Theactivityofthisenzymewasdetermined
by monitoring the increase in absorbance at 340nm. The
activity of GST was expressed in terms of n mol NADPH
consumed/min/mg protein.
4.8.12. Quantitative Estimation of DNA Fragmentation Assay
by Diphenylamine (DPA) Assay. The diphenylamine (DPA)
reaction of lymphocytes was performed by the method of
Peradones et al., 1993 [46]. Perchloric acid (0.5M) was
added to the sample containing uncut DNA (resuspended
in 200μL of hypotonic lysis buﬀer) and to the other half
of the supernatant-containing DNA fragments. Then two
volumes of a solution consisting of 0.088M DPA, 98% (v/v)
glacialaceticacid,1.5%(v/v)sulphuricacid,anda0.5%(v/v)
concentration of 1.6% acetaldehyde solution were added.
The samples were stored at 4◦Cf o r4 8h .T h er e a c t i o nw a s
quantiﬁedspectrophotometricallyat575nm.Thepercentage
of fragmentation was calculated as the ratio of DNA in the
supernatants to the total DNA.
4.8.13. DNA Fragmentation Study by Agarose Gel Electropho-
resis. DNA gel electrophoresis was performed as described
in our previous lab report [47]. In brief, after the treatment
schedule, the lymphocytes were resuspended in 270μLp r e -
cooled lysis buﬀer (10mM Tris-HCl, 10mM NaCl, 10mM
E D T A ,p H7 . 4 )w i t h3 0 μL SDS (10%). RNase A (ﬁnal
concentration 100μg/mL) was then added, and incubation
was continued at 45◦C for 45min. Subsequently, proteinase
K (ﬁnal concentration 100μg/mL) was added to the cell
lysate, and incubation was continued at 50◦C for overnight
to complete digestion. DNA was isolated from the lysate
using phenol/chloroform/iso-amyl alcohol. Then, DNA was
precipitated with one volume of 10M sterile ammonium
acetate, and two volumes of absolute ethanol followed by
centrifugation at 13000×gf o r1 0m i na t4 ◦C. The extracted
DNA samples were washed with 70% ethanol and dissolved
in 50μLT Eb u ﬀer (10mM Tris-HCl, 1mM EDTA, pH
7.6). Gel loading buﬀer (10mM EDTA, 0.25% bromophenol
blue, 30% glycerol) was then added to the DNA sample
at 1:5 ratio and loaded onto a 1.2% agarose gel. The
electrophoresis was carried out at 50V for 90min in TBE
buﬀer(90mMTris-HCl,2mMEDTA,90mMboricacid,pH
8.0). 100bp molecular weight markers (Genai, Bangalore,
India) were used. After electrophoresis, DNA was visualized
by soaking the gel in TBE buﬀer containing 1.5μg/mL
ethidium bromide in UV light, and the picture was captured
in Bio-Rad gel documentation system.
4.8.14. Protein Estimation. Protein was determined accord-
ing to Lowry et al., 1951 using bovine serum albumin as
standard [48].
4.9. Statistical Analysis. T h ed a t aw e r ee x p r e s s e da sm e a n±
standard error, n = 6. Comparisons of the means of control,
andexperimentalgroupsweremadebytwo-wayANOVAtest
(using a statistical package, Origin 6.1, Northampton, MAOxidative Medicine and Cellular Longevity 13
01060 USA) with multiple comparison t-tests; P<0.05 as a
limit of signiﬁcance.
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